Medullary carcinoma of the breast: a brief report from a tertiary care center.
暂无分享,去创建一个
[1] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[2] E. Winer,et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Bold,et al. Medullary carcinoma of the breast: a population-based perspective , 2011, Medical oncology.
[4] E. Perez,et al. 5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976) , 2011 .
[5] H. Rugo,et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Trifiro,et al. Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature. , 2004, The Journal of clinical endocrinology and metabolism.
[7] C. Hudis,et al. Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Soares,et al. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] M. Burt,et al. REGRESSION OF UTERINE LOW‐GRADE SMOOTH‐MUSCLE TUMORS METASTATIC TO THE LUNG AFTER OOPHORECTOMY , 1997, Obstetrics and gynecology.
[10] E. Gunel,et al. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] D. Delbeke,et al. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. , 1996, Chest.
[12] B. Fisher,et al. Medullary cancer of the breast revisited , 1990, Breast Cancer Research and Treatment.
[13] P. Rosen,et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. , 1977, Cancer.